Camptothecin analogues (CPT) are a class of highly potent anti-cancer drugs used to treat a range of cancers. Today, the administration of chemotherapy for first or second line therapy is not based on predictive biomarkers. Additionally, the mechanism of resistance towards the CPT class of drugs is not understood. As a result, mis-prescribed therapies lead to either metastasis or no response from treatment.
By decoding the mechanism for CPT resistance, the Predictus team has developed a companion diagnostic tool which can help healthcare providers personalize cancer patients’ treatment. Utilizing Predictus’ novel predictive biomarker technology, the team is developing antibody conjugated drugs which will, together, revolutionize the diagnosis and treatment of various cancers.